From BioFIT meetings to a veterinary licensing partnership: the story of Can-Fite BioPharma & Vetbiolix
Sometimes, a single meeting can lead to a partnership with long-term scientific and commercial impact.
That is exactly what happened when Can-Fite BioPharma participated in BioFIT. Discussions initiated during the event led directly to a veterinary licensing partnership with Vetbiolix for Piclidenoson, the company’s drug candidate being developed for the treatment of osteoarthritis in dogs and cats.
The agreement, estimated at $325 million in potential royalty revenues, demonstrates how meaningful connections made during a partnering event can evolve into major business opportunities.
From partnering meetings to a strategic licensing agreement
BioFIT brings together pharmaceutical and biotech companies, technology transfer professionals, research organisations and investors with one common objective: creating new partnerships that accelerate innovation.
For Can-Fite BioPharma, those discussions resulted in a concrete licensing agreement with Vetbiolix, enabling the company to expand the development of Piclidenoson into the veterinary market.
As Dr. Sari Fishman, VP of Business Development at Can-Fite BioPharma, explains:
“Our previous participation at BioFIT led directly to our successful partnership with Vetbiolix for Piclidenoson for the treatment of osteoarthritis in dogs and cats.”
Returning to BioFIT to build the next partnership
The story did not end with this first success.
Building on the partnership with Vetbiolix, Can-Fite returned to BioFIT 2025 to explore new veterinary collaboration opportunities for Namodenoson, its Phase III anti-cancer drug candidate, with the ambition of expanding its veterinary pipeline.
This illustrates another key strength of BioFIT: participants don’t simply attend once. Many return year after year because each edition offers new opportunities to connect with potential partners, explore new markets and advance their business development objectives.
Where future partnerships begin
Every year, BioFIT brings together key decision-makers from across the Life Sciences ecosystem to facilitate research collaborations, licensing agreements, investment opportunities and strategic partnerships.
The story of Can-Fite BioPharma and Vetbiolix is another example of how a conversation initiated at BioFIT can evolve into a partnership with lasting impact.
Whether you are looking for a licensing partner, a research collaboration, an investor or new business opportunities, BioFIT provides the environment to meet the right people and turn conversations into concrete outcomes.
Join BioFIT 2026 on December 10th and 11th in Marseille and start your next partnership.
